Epidemiology and Prognosis of Intensive Care Unit–Acquired Bloodstream Infection
Hatem Kallel, F. Djossou(University of French Guiana), Michaella Roy(University of French Guiana), Dabor Résière(Centre Hospitalier Universitaire de Martinique), Claire Mayence(University of French Guiana), Cyrille Mathien(University of French Guiana), Joy Mootien(Centre Hospitalier de Mulhouse), Stéphanie Houcke(University of French Guiana), Didier Hommel(University of French Guiana), Magalie Demar
Cited by 34
Related Papers
Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy
|Journal of Infection|2016|167
Ventilator-Associated Events
|Critical Care Medicine|2015|147
Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020
|Eurosurveillance|2020|129
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
|Clinical Microbiology and Infection|2021|107
Targeted temperature management in the ICU: guidelines from a French expert panel
|Annals of Intensive Care|2017|72